Free Trial
NASDAQ:REPL

Replimune Group Q1 2026 Earnings Results & Report

Replimune Group logo
$21.78 -1.50 (-6.44%)
Closing price 11/11/2026 04:00 PM Eastern
Extended Trading
$21.74 -0.04 (-0.16%)
As of 11/11/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Replimune Group missed analyst earnings expectations in its Q1 2026 results, released August 7, 2025. The company reported EPS of -$0.95 versus the -$0.83 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Replimune Group EPS Results

Actual EPS
-$0.95
Consensus EPS
-$0.83
Beat/Miss
Missed by -$0.12
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Replimune Group Revenue Results

Actual Revenue
N/A
Expected Revenue
$500 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Replimune Group Q1 2026 Earnings FAQ

Replimune Group (NASDAQ:REPL) reported earnings of -$0.95 per share for Q1 2026, missing the consensus estimate of -$0.83. The report was announced on Thursday, August 7, 2025.

Replimune Group Earnings Headlines

Short Interest Powder Kegs: 10 Stocks Bears Cannot Quit Buying
The warning signs most investors see too late
Dr. Martin D. Weiss has publicly predicted six major American crashes since founding Weiss Ratings in 1971. Now, after 55 years of market analysis, he says conditions are forming for a financial crisis that could rival or exceed 2008.tc pixel
Cramer's lightning round: Buy FedEx Freight
See More Replimune Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Replimune Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Replimune Group and other key companies, straight to your email.

About Replimune Group

Replimune Group (NASDAQ:REPL) is a biotechnology company focused on developing tumor-directed immunotherapies for people with cancer. Its proprietary platform uses genetically modified herpes simplex viruses, designed to be injected into tumors and stimulate an immune response against cancer.

The company’s investigational pipeline includes RP1, an engineered oncolytic virus that expresses proteins intended to promote tumor cell destruction and immune activation. Replimune is also developing other candidates that combine virus-based treatment with additional immune-stimulating approaches. These programs remain investigational and are being evaluated in clinical studies.

Founded in 2015, Replimune is headquartered in Woburn, Massachusetts. Its work centers on research and clinical development rather than marketed products or services.

View Replimune Group Profile